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Summary 
Background ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate 
cancer cells through high-aﬃ nity binding to the AR and inhibition of AR nuclear translocation. This trial 
assessed ODM-201’s safety, pharmacokinetics, and activity in men with metastatic castration-resistant 
prostate cancer. 
Methods  
The ARADES trial is an open-label phase 1–2 trial undertaken in 23 hospitals across Europe and USA with 
ongoing long-term follow-up. Men with progressive metastatic castration-resistant prostate cancer, who had 
castrate concentrations of testosterone and an Eastern Cooperative Oncology Group score of 0–1 were 
enrolled. In the phase 1 part of the trial, patients were given oral ODM-201 at a starting daily dose of 200 mg, 
which was increased to 400 mg, 600 mg, 1000 mg, 1400 mg, and 1800 mg. In phase 2, patients were 
randomly assigned centrally and stratiﬁ ed by previous chemotherapy and treatment with CPY17 inhibitors, 
to receive one of three daily doses of ODM-201 (200 mg, 400 mg, and 1400 mg). The primary endpoint in 
phase 1 was safety and tolerability, whereas in phase 2 it was the proportion of patients with a PSA 
response (50% or greater decrease in serum PSA) at week 12. All analyses included patients who had 
received at least one dose of ODM-201. This trial is registered with ClinicalTrials.gov, number 
NCT01317641, and NCT01429064 for the follow-up after 12 weeks. 
  
  
 
 
Findings  
We enrolled patients between April 5, 2011, and March 12, 2013. In phase 1, 24 patients were enrolled to six 
sequential cohorts of three to six patients and received a daily dose of ODM-201, 200–1800 mg. No dose-
limiting toxic eﬀ ects were reported and the maximum tolerated dose was not reached. In phase 1, three 
patients reported eight adverse events of grade 3 (fracture, muscle injury, laceration, paralytic ileus, pain, 
presyncope, urinary retention, and vomiting) and one patient had a grade 4 adverse event (lymphoedema). 
None of the grade 3–4 adverse events were deemed to be related to ODM-201. Of the phase 1 patients, the 
four who received 200 mg, seven who received 400 mg, and three who received 1400 mg entered the phase 
2 part of the trial. In addition to these patients, 110 were randomly assigned to three groups: 200 mg (n=38), 
400 mg (n=37), and 1400 mg (n=35). For these patients, the most common treatment-emergent adverse 
events were fatigue or asthenia (15 [12%] of 124 patients), hot ﬂ ush (six [5%]), and decreased appetite (ﬁ ve 
[4%]). One patient (<1%) had a grade 3 treatment-emergent adverse event (fatigue); no patients had a 
treatment-emergent grade 4 adverse event. 38 patients who received 200 mg, 39 who received 400 mg, and 
33 who received 1400 mg were assessable for PSA response at 12 weeks. 11 (29%) patients in the 200 mg 
group, 13 (33%) in the 400 mg group, and 11 (33%) in the 1400 mg group had a PSA response at 12 weeks. 
Interpretation Our results suggest that ODM-201 monotherapy in men with progressive metastatic castration-
resistant prostate cancer provides disease suppression and that ODM-201 has a favourable safety proﬁ le. 
These ﬁ ndings support further investigation of clinical responses with ODM-201 in men with castration-
resistant prostate cancer. 
 
Introduction 
Prostate cancer is the most common cancer in European men, accounting for an estimated 416 700 new 
diagnoses every year (23% of all new cancer cases in men) and is a leading cause of cancer-related deaths 
(estimated 92 200 deaths per year).
1
 Most patients with advanced prostate cancer are initially treated with 
androgen-deprivation therapy via orchiectomy or a luteinising hormone-releasing hormone (LHRH) agonist 
or antagonist .
2,3
 However, despite castrate levels of serum testosterone, nearly all men with advanced 
disease eventually develop metastatic castration-resistant prostate cancer. Until recently, treatment options 
with proven efficacy for patients with this disorder were limited to docetaxel plus prednisone and zoledronate. 
However, several new treatment options with different mechanisms of action have recently become 
available, including abiraterone acetate (abiraterone),
4
 sipuleucel-T,
5
 cabazitaxel,
6
 denosumab,
7
 
enzalutamide,
8
 and radium (223Ra) dichloride.
9
 Metastatic castration-resistant prostate cancer is associated 
with continued expression of the androgen receptor (AR), and tumour growth remains dependent on AR 
signalling.
10,11
 Several treatments targeting the AR axis such as abiraterone and enzalutamide have shown 
improved survival in metastatic castration-resistant prostate cancer.
4, 8,12
 The mechanisms behind continued 
AR signalling in metastatic castration-resistant prostate cancer can include adrenal or intratumoural 
androgen synthesis, increased AR expression due to gene amplification or other mechanisms, and 
constitutive AR activation due to splice variants or activating mutations.
10,13
 Other identified mechanisms of 
resistance to castration include indirect activation via non-AR pathways and cell cycle activation.
14
 Recently, 
a Phe876Leu missense mutation in the ligand-binding domain of AR has been described. This mutation 
confers resistance to enzalutamide and ARN-509 in LNCaP cell lines overexpressing wild-type AR as 
models of prostate cancer.
15
  
In the past decade, several second-generation AR inhibitors, such as enzalutamide,
16
 have been developed 
to provide improved mechanisms of action. ODM-201 is a novel, new-generation AR inhibitor that is 
structurally distinct from enzalutamide and was selectively developed for the treatment of castration-resistant 
prostate cancer.
17,18,19
 ODM-201 is a mixture (1:1) of two pharmacologically active diastereomers: ORM-
16497 and ORM-16555. ODM-201 (both diastereomers) and its major metabolite, ORM-15341, have a 
  
 
higher AR-binding affinity than do bicalutamide, enzalutamide, and ARN-509.
18,19
 Additionally, ODM-201 
inhibits nuclear translocation of AR in AR-overexpressing cells and significantly inhibits tumour growth in the 
murine VCaP CRPC xenograft model. Non-clinical data have also shown negligible penetrance of ODM-201 
through the blood–brain barrier, thus suggesting a low risk of seizure.
18,19
  
On the basis of promising preclinical data, we started a phase 1–2 clinical trial (ARADES) to assess ODM-
201 in men with progressive metastatic castration-resistant prostate cancer. The primary objectives of the 
phase 1–2 trial were to assess safety and tolerability and to define a maximum tolerated dose. Secondary 
objectives were to assess the pharmacokinetics of ODM-201 and to assess the antitumour activity of ODM-
201 as identified by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone 
lesions, and by changes in circulating tumour cell counts. 
Methods 
Patients 
ARADES was an open-label, multicentre trial with a non-randomised phase 1 dose escalation portion, a 
phase 2 randomised dose expansion, and long-term follow-up. Patients were enrolled at 23 hospitals in 
Europe and the USA. Eligible men aged 18 years or older had histologically confirmed adenocarcinoma of 
the prostate and progressive metastatic disease despite ongoing androgen-deprivation therapy (LHRH 
analogue or antagonist, which was continued throughout the treatment, or orchiectomy) with serum 
testosterone concentrations lower than 0·50 ng/mL (<1·7 nmol/L). We defined disease progression in soft-
tissue by modified Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) or in bone by two or 
more new lesions identified by radionuclide bone scan or a rising PSA. The criteria for rising PSA was PSA 
higher than 2 ng/mL in at least two successive rising measurements, taken at least 1 week apart. Patients 
had to have received previous first generation antiandrogen treatment, had antiandrogen withdrawal, and up 
to two previous chemotherapy regimens. Other eligibility criteria were Eastern Cooperative Oncology Group 
(ECOG) performance status 0 or 1 and no previous therapy with enzalutamide or an investigational AR 
inhibitor. We did not exclude patients with a history or risk of seizure. The appendix shows full inclusion and 
exclusion criteria. 
The trial was approved by the investigational review board or independent ethics committee of each 
participating centre, and competent authorities. The trial was done according to the principles of the 
Declaration of Helsinki and in compliance with guidelines for Good Clinical Practice. All patients provided 
written informed consent. 
Randomisation and masking 
The treatment allocation lists were created and randomisation was done centrally at Orion Corporation Orion 
Pharma. For the phase 1 dose-escalation part of the study, no randomisation was done. The patients 
entered the phase 1 in the order we found them to be eligible. In the phase 2, before the third expanded 
dose level was determined, patients were randomly assigned (ratio 1:1) by blocks of four and two to 200 mg 
or 400 mg daily doses of ODM-201 with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; 
post-chemotherapy and CYP17 inhibitor-naive; and post-CYP17 inhibitor) as stratification factors. Once we 
had identified the third expanded dose level, patients were randomly assigned to 200 mg, 400 mg, or 1400 
mg daily doses, at an allocation ratio that accounted for how many blocks were already used, with the three 
previous treatments as stratification factors. 
Procedures 
In the open-label phase 1 part, sequential dose-escalation cohorts of three to six patients were given oral 
ODM-201 (with food twice daily, eg, 200 mg daily dose=100 mg twice a day) at a starting daily dose of 200 
mg, which was increased to 400 mg, 600 mg, 1000 mg, 1400 mg, and 1800 mg. 
  
 
Patients who did not experience dose-limiting toxicity (DLT), defined as treatment-related toxic effects of 
grade 3 or higher, within the first 28 days were permitted to continue ODM-201 treatment in the absence of 
disease progression or any intolerable adverse events. We did not permit any intrapatient dose escalation. 
The next dose level was started after a minimum of three patients had completed 28 days of treatment and 
after safety review by the independent data and safety monitoring board. 
The phase 2 part included three expanded cohorts (200 mg, 400 mg, and 1400 mg daily dose) each 
containing about 35 patients. We selected the 200 mg and 400 mg daily doses as the two lower dose levels 
for the phase 2 part while dose escalation was ongoing in the phase 1 part, based on at least 50% PSA 
response, good tolerability, and the pharmacokinetics noted at these doses. After completion of the phase 1 
dose escalation, we selected the dose of 1400 mg daily as the third dose for phase 2 on the same basis as 
the other dose levels. 
We classified adverse events by system organ classes and preferred terms (Medical Dictionary for 
Regulatory Activities coding system) and graded by National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE version 4.03). A central ECG laboratory recorded and read 
electrocardiograms, using a 12-lead Holter system (in the 1400 mg and 1800 mg dose-escalation cohorts). 
We did laboratory assessments (haematology, serum chemistry, hormones, and urine tests) at baseline, 
once a week for the first 28 days, then every 4 weeks until 9 months and every 3 months thereafter, plus at 
the end-of-study visit. 
We did PSA measurements every 4 weeks until 9 months, and every 3 months thereafter. We assessed 
changes in serum PSA as percentage change in PSA at 12 weeks from baseline. PSA was analysed 
centrally, and we only used these central values for the analyses. We assessed soft-tissue response using 
modified RECIST (version 1.1) in chest, abdomen, and pelvic CT or MRI scans, done at baseline, week 12, 
and every 3 months thereafter. We assessed bone disease by changes in lesions on bone scans done at 
baseline, week 12, and every 3 months thereafter; we defined progression by the appearance of two or more 
new lesions compared with a previous scan. There was a 12-week minimum treatment period before PSA or 
radiological progression was declared. We measured circulating tumour cell count per 7·5 mL of blood using 
the CellTracks system (CellSearch assay, Veridex, NJ, USA) from blood samples obtained at baseline and 
week 12. We defined median time to PSA progression as the time from start of ODM-201 treatment until 
documentation of a 25% increase or higher and an absolute increase of 2 ng/mL or higher in PSA from the 
nadir (Prostate Cancer Working Group [PCWG2] criteria)20 and also as the time from start of ODM-201 
treatment until documentation of a 25% increase or higher in PSA from baseline, representing an absolute 
increase of at least 2 ng/mL. 
We obtained blood samples for the pharmacokinetics analyses. We identified plasma concentrations of 
diastereomers ORM-16497 and ORM-16555, and the major metabolite ORM-15341 by liquid 
chromatography–tandem mass spectrometry (LC-MS/MS); ODM-201 concentration was the sum of ORM-
16497 and ORM-16555 concentrations. 
Outcomes 
In phase 1, the primary outcome was safety and tolerability of ODM-201 including the frequency and severity 
of adverse events, plus any clinically significant changes in vital signs, electrocardiographs, and laboratory 
values. The secondary outcome was the pharmacokinetics of ODM-201. 
In phase 2, the primary outcome was PSA response at week 12, defined as a decrease of 50% or more in 
serum PSA from baseline. Secondary outcomes were the objective disease response, as assessed by 
RECIST for soft tissue and by PCWG2 criteria for bone, time to PSA progression analysed using PCWG2 
criteria, and time to radiographic disease progression by RECIST and PCWG2 criteria. 
Statistical analysis 
  
 
Activity and safety were assessed in a population that consisted of all patients who received at least one 
dose of ODM-201 treatment. The pharmacokinetic population consisted of patients who had no major 
protocol violations affecting pharmacokinetic outcomes and had a sufficient number of data points for the 
pharmacokinetic variables to be determined. We used this population for all pharmacokinetic analyses. PSA 
response rate is presented as a percentage of patients with a response at week 12 with the corresponding 
95% CI based on the binomial distribution. We used the Kaplan-Meier method to estimate the progression 
curves. We did not deem early increases in PSA before 12 weeks to be PSA progression. We summarised 
all safety and secondary outcomes descriptively. We did all analyses with SAS for Windows, version 9.4. For 
the phase 2 part, a sample size of eight assessable patients per dose in each stratification group would 
provide 80% confidence to reject a PSA response rate of 55% or less at a 1-sided significance level of 0·2, 
assuming a true PSA response rate of 70%. This trial and its follow-up are registered with ClinicalTrials.gov, 
number NCT01317641 for the trial and NCT01429064 for its follow-up. 
Role of the funding source 
The trial funders contributed to the design, conduct, analysis, and interpretation of the data. The 
corresponding author had full access to the data and had final responsibility for the decision to submit for 
publication. 
Results 
We enrolled patients from April 5, 2011, to March 12, 2013. Altogether 201 patients were screened and 136 
enrolled (24 were enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 
mg, 400 mg, or 1400 mg of ODM-201; figure 1). Two patients who were randomly assigned to treatment did 
not start ODM-201, and were therefore excluded from efficacy and safety analyses. Of the phase 1 patients, 
four who received 200 mg, seven who received 400 mg, and three who received 1400 mg entered the phase 
2 part of the trial, bringing the total number of patients at expanded dose levels assessed for activity and 
safety to 124 patients and the number assessed for safety to 134 patients (all dose levels, appendix). The 
cutoff date for the data included in this report was Oct 4, 2013. The median time on ODM-201 treatment was 
24·8 months (IQR 24·8–25·2) in the phase 1 and 11·0 months (IQR 8·3–14·0) in the phase 2. Altogether, 76 
(57%) of 134 patients continued treatment for more than 12 weeks, and 36 (27%) of 134 patients were still 
receiving ODM-201 treatment at the time of data cutoff (Oct 4, 2013). The most common reason for 
discontinuation was disease progression, and only five (4%) of 124 patients discontinued because of an 
adverse event. Investigators at study sites did not deem these adverse events leading to discontinuation to 
be related to ODM-201. No dose reductions were required for any patient. 
  
  
 
 
Figure 1.  
Trial profile 
(A) Phase 1. (B) Phase 2. *Included in phase 2 analyses of safety and efficacy. †One patient not treated. 
 
Table 1 shows the baseline characteristics of 24 patients enrolled in the phase 1 dose escalation part. ODM-
201 was tolerated up to the highest pre-specified dose level of 1800 mg, and the maximum tolerated dose 
was not reached. Most adverse events (116 [93%] of 125) were grade 1–2. The most common adverse 
events were fatigue or asthenia in ten (42%) of 24 patients, diarrhoea in seven (29%) patients, arthralgia in 
six (25%) patients, back pain in six (25%) patients, and headache in five (21%) patients. Three (13%) 
patients reported eight adverse events of grade 3 (fracture, muscle injury, laceration, paralytic ileus, pain, 
presyncope, urinary retention, and vomiting) and one (4%) patient had a grade 4 adverse event 
(lymphoedema). None of the grade 3–4 adverse events were deemed to be related to ODM-201. Two (8%) 
patients discontinued treatment because of adverse events (bone pain and severe infection). No dose-
limiting toxic effects were reported and no dose-related trends were noted for any adverse events.  
 
  
 
Table 1. Baseline characteristics Phase 1 
(n=24) 
Phase 2
 
 200 mg group 
(n=38) 
400 mg group 
(n=37) 
1400 mg group (n=35) 
Age (years) 69 (64–74) 67 (65–73) 68 (64–75) 73 (64–78) 
PSA (ng/mL) 27 (13–96) 109 (43–352) 95 (45–255) 155 (31–382) 
LDH (U/L) 249 (192–412) 220 (195–292) 232 (202–322) 226 (201–322) 
Albumin (g/L) 38 (36–44) 38 (35–42) 38 (36–41) 41 (35–44) 
Chemotherapy-naive and CYP17 inhibitor-naive 14 (58%) 11 (29%) 9 (24%) 8 (23%) 
Post-chemotherapy and CYP17 inhibitor-naive 7 (29%) 9 (24%) 9 (24%) 10 (29%) 
Post-CYP17 inhibitor 3 (13%) 18 (47%) 19 (51%) 17 (49%) 
Previous lines of chemotherapy 10 (42%) 24 (63%) 25 (68%) 21 (60%) 
 One line 9 (38%) 20 (53%) 23 (62%) 18 (51%) 
 Two lines 1 (4%) 4 (11%) 2 (5%) 3 (9%) 
Total Gleason score at diagnosis 
 <8 15 (68%) 15 (42%) 20 (59%) 15 (46%) 
 ≥8 7 (32%) 21 (58%) 14 (41%) 18 (55%) 
 Missing
*
 2 2 3 2 
Initial therapy 
 Prostatectomy 6 (25%) 5 (13%) 8 (22%) 2 (6%) 
 Orchiectomy 1 (4%) 3 (8%) 1 (3%) 2 (6%) 
 Medical castration 9 (38%) 23 (61%) 16 (43%) 18 (51%) 
 Radiotherapy 3 (13%) 3 (8%) 10 (27%) 7 (20%) 
 Other 5 (21%) 4 (11%) 2 (5%) 6 (17%) 
Time from diagnosis to start of ODM-201 
treatment (months) 
86 (10–231) 53 (40–90) 74 (35–113) 57 (29–100) 
Previous hormonal therapy 
 Ketoconazole 3 (13%) 3 (8%) 0 1 (3%) 
 GnRH 24 (100%) 36 (95%) 35 (95%) 32 (91%) 
First generation antiandrogen 24 (100%) 38 (100%) 37 (100%) 35 (100%) 
 One line 9 (38%) 23 (61%) 26 (70%) 25 (71%) 
 >one line 15 (62%) 15 (39%) 11 (30%) 10 (29%) 
 Oestrogens 7 (29%) 4 (11%) 5 (14%) 6 (17%) 
ECOG performance status 
 0 17 (71%) 19 (50%) 20 (54%) 16 (46%) 
 1 7 (29%) 19 (50%) 17 (46%) 19 (54%) 
Circulating tumour cell count 
 <5 cells per 7·5 mL of blood 13 (54%) 18 (47%) 18 (49%) 16 (46%) 
 ≥5 cells per 7·5 mL of blood 9 (38%) 17 (45%) 17 (46%) 14 (40%) 
 NA 2 (8%) 3 (8%) 2 (5%) 5 (14%) 
Disease localisation 
 Bone disease 15 (63%) 34 (89%) 32 (86%) 32 (91%) 
  
 
Data are number of patients (%) or median (IQR). PSA=prostate-specific antigen. LDH=lactate dehydrogenase. GnRH=gonadotropin-
releasing hormone. ECOG=Eastern Cooperative Oncology Group. NA=not assessable. 
*Gleason score not available. †Or non-countable (one in phase 1 and 28 in phase 2). 
 
In the pharmacokinetic analysis, ODM-201 was rapidly absorbed and the median tmax were 3.0–5.1 h for 
ODM-201 and 1·5–5·0 h for ORM-15341 on day 1. The mean metabolite:parent ratio (area under the curve, 
AUC) at steady state was 1.6–2.3:1. The exposure of ODM-201 (AUCt and Cmax) at steady state increased 
in a linear, dose-related manner up to 1400 mg daily dose (figure 2). Exposure was similar after the 1800 mg 
daily dose compared with after the 1400 mg daily dose. Dose escalation was discontinued because of a 
plasma concentration plateau of ODM-201. Steady-state plasma concentrations were reached after 1 week 
of continuous treatment, with no increase noted between 2 and 4 weeks. The mean half-life of ODM-201 was 
independent of dose, being 15·8 h (SD 13·8) at steady state after 200–1800 mg daily doses. The mean half-
life of ORM-15341 was 10·0 h (3·8) at steady state after 200–1800 mg daily doses. 
  
 Bone only 6 (25%) 12 (32%) 11 (30%) 20 (57%) 
 Bone and soft tissue 9 (38%) 22 (58%) 21 (57%) 12 (34%) 
 Soft-tissue disease 17 (71%) 26 (68%) 26 (70%) 15 (43%) 
 Lymph node 17 (71%) 18 (47%) 24 (65%) 7 (20%) 
 Visceral 1 (4%) 10 (26%) 8 (22%) 8 (23%) 
 No radiological evidence of metastases 1 (4%) 0 0 0 
Bone metastases 
 0 9 (38%) 6 (16%) 5 (14%) 3 (9%) 
 1–4 3 (13%) 10 (26%) 13 (35%) 6 (17%) 
 5–20 7 (29%) 11 (29%) 9 (24%) 8 (23%) 
 >20
†
 5 (21%) 11 (29%) 10 (27%) 18 (51%) 
  
 
  
Figure 2. Pharmacokinetics of ODM-201 at steady state in the phase 1 population. (A) Mean steady state concentrations of ODM-201. 
(B) ODM-201 mean Cmax by dose. (C) ODM-201 mean area under the curve by dose. Datapoints are means and whiskers depict SDs 
 
. 
  
 
 
Anticancer activity was noted across all of the six doses. We noted a PSA response (reduction of at least 
50% in serum PSA) in 17 (71%) patients at 12 weeks, when including the three patients without a PSA 
sample who were discontinued before the 4-week visit in phase 1 (one in each 200 mg, 400 mg, and 1000 
mg dose group). A PSA response was noted in 17 (81%) of the 21 patients who had PSA samples at 
baseline and week 12. Additionally, in 31 evaluable patients, an early response to ODM-201 was noted 
based on similar 50% or higher reduction in PSA at weeks 4 across all levels (n=15, 71%) and 8 (n=16, 
80%). 
Table 1 shows the baseline characteristics of patients enrolled in the phase 2 part of the study. 
Characteristics by previous treatment regimens are shown in the appendix. ODM-201 was well tolerated in 
all expanded cohorts (table 2). The appendix shows the adverse events for the total safety population 
including all dose levels. Most adverse events (728 [91%] of 796) were grade 1–2. The most common 
adverse events (all grades)were fatigue or asthenia in 38 (31%) of 124 patients, back pain in 26 (21%) 
patients, arthralgia in 19 (15%) patients, pain in 18 (15%) patients, and constipation in 17 (14%) patients 
(one patient could have had adverse events of several grades). No differences were observed between 
groups when examined by dose or by previous treatment. The investigators deemed most adverse events to 
be related to prostate cancer. Adverse events related to ODM-201 (by investigator's judgment) were reported 
in 44 (35%) patients, including fatigue or asthenia in 15 (12%) patients, hot flush in six (5%) patients, 
decreased appetite in five (4%) patients, diarrhoea in three (2%) patients, and headache in three (2%) 
patients. No seizures were noted during the trial. Adverse events of grade 3 were reported in only 27 (22%) 
patients and adverse events of grade 4 in two (<2%) patients. No grade 4 adverse events and only one 
grade 3 adverse event (fatigue or asthenia) were deemed to be related to ODM-201. Four (3%) patients died 
because of progression of prostate cancer, of which three died within 30 days after ODM-201 was 
discontinued. Three (2%) patients discontinued the trial because of adverse events (fatigue, cauda equina 
syndrome, and colitis). None of these discontinuations were deemed related to ODM-201. 
Table 2. Adverse events occurring in 5% or more patients: expanded dose levels, safety population (n=124) 
 Grade 1 Grade 2 Grade 3 
Fatigue or asthenia 27 (22%) 13 (10%) 2 (2%) 
Back pain 16 (13%) 13 (10%) 2 (2%) 
Arthralgia 15 (12%) 9 (7%) 2 (2%) 
Pain 8 (6%) 8 (8%) 2 (2%) 
Constipation 14 (11%) 5 (4%) 0 
Decreased appetite 15 (12%) 1 (<1%) 0 
Nausea 12 (10%) 4 (3%) 0 
Peripheral oedema 13 (10%) 2 (2%) 0 
Insomnia 7 (6%) 6 (5%) 1 (<1%) 
Musculoskeletal pain 9 (7%) 3 (2%) 0 
Anaemia 0 8 (6%) 3 (2%) 
Diarrhoea 9 (7%) 0 0 
Vomiting 8 (6%) 0 1 (<1%) 
Weight loss 8 (6%) 1 (<1%) 0 
Hot flush 6 (5%) 3 (2%) 0 
Muscular weakness 4 (3%) 3 (2%) 1 (<1%) 
Hypertension 1 (<1%) 7 (6%) 1 (<1%) 
Pain in extremity 5 (4%) 4 (3%) 0 
Headache 5 (5%) 1 (<1%) 1 (<1%) 
  
 
Dyspnoea 5 (4%) 1 (2%) 0 
Urinary tract infection 7 (6%) 0 0 
Data are number of patients (%). 
 
We noted a PSA response (≥ 50% decrease in PSA) by week 12 with all doses and all treatment groups, but 
significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were 
naïve to both chemotherapy and CYP17 inhibitors, and those who had previously received chemotherapy 
but not CYP17 inhibitors (figure 3 and table 3). We noted the best PSA responses at 1400 mg in patients 
naive to both chemotherapy and CYP17 inhibitor (table 3). Eight patients (22%) who were naive to both 
chemotherapy and CYP17 inhibitor, seven (22%) who had been treated with chemotherapy but not CYP17 
inhibitors, and 30 (55%) in who had received a CYP17 inhibitor did not have a decrease in PSA during the 
first 12 weeks. No clear dose response was noted in CYP17 inhibitior-naive patients previously treated with 
chemotherapy and in patients who received CYP17 inhibitor. The appendix shows percentage change in 
PSA at weeks 4, 8, and 12 from baseline. 
 
 
 
Figure 3.  
Percentage change in PSA at week 12 from baseline. 
(A) Chemotherapy-naive and CYP17i-naive patient group. (B) Post-chemotherapy and CYP17i-naive patient group. (C) Post-
CYP17i patient group. Includes patients carried forward from phase 1.  
PSA=prostate-specific antigen. CYP17i=cytochrome P450 17A1 inhibitor. *Data truncated at 100%. 
 
 
Table 3. 
PSA decreases from baseline at 12 weeks: expanded dose levels 
 
 200 mg group 400 mg group 1400 mg group 
Chemotherapy-naive and CYP17i-naive 
Number of evaluable patients 12 13 7 
≥90% 0 6 (46%) 3 (43%) 
≥50% 6 (50%) 9 (69%) 6 (86%) 
≥30% 7 (58%) 10 (77%) 6 (86%) 
Post-chemotherapy and CYP17i-naive 
Number of evaluable patients 11 9 11 
≥90% 0 0 2 (18%) 
≥50% 5 (45%) 1 (11%) 4 (36%) 
  
 
 
 
 
 
 
 
 
 
CYP17i=cytochrome P450 17A1 inhibitor. 
 
RECIST responses or stable disease in soft tissue, and stabilised disease in bone are shown in table 4. No 
clear differences in response by dose were noted in soft tissue and bone; although this variable was not 
formally analysed because of the small number of patients within each dose group and subgroup. The 
highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients 
(table 4). We noted one complete response (17%; 200 mg dose group) and two partial responses (33%; 400 
mg and 1400 mg dose groups) in patients who were chemotherapy and CYP17 inhibitor-naive with visceral 
disease. One partial response (17%; 1400 mg) occurred in a patient who had received chemotherapy but not 
a CYP17 inhibitor. We did not note any responses in patients with visceral disease who had already received 
a CYP17 inhibitor. 
 
Table 4. 
Imaging results at week 12 
  200 mg group 400 mg group 1400 mg group 
Chemotherapy-naive and CYP17i-naive (n=37) 
Number of patients with soft tissue evaluable 9 9 2 
RECIST response 
 CR+PR 1 (11%) 4 (44%) 1 (50%) 
 CR+PR+SD 9 (100%) 6 (67%) 2 (100%) 
Number of patients evaluable for bone scan 11 10 7 
 No change 10 (91%) 7 (70%) 6 (86%) 
Post-chemotherapy and CYP17i naive (n=32) 
Number of patients with soft tissue evaluable 8 7 5 
RECIST response 
 CR+PR 1 (13%) 0 1 (20%) 
 CR+PR+SD 5 (63%) 3 (20%) 4 (20%) 
Number of patients evaluable for bone scan 9 7 10 
 No change 5 (56%) 4 (20%) 7 (20%) 
Post-CYP17i (n=55) 
Number of patients with soft tissue evaluable 13 12 9 
RECIST response 
 CR+PR 0 2 (17%) 0 
 CR+PR+SD 5 (38%) 9 (75%) 6 (67%) 
Number of patients evaluable for bone scan 11 15 11 
 No change 5 (45%) 9 (60%) 6 (55%) 
Data are number of patients (%), unless otherwise indicated. CR=complete response. PR=partial response. SD=stable disease. 
CYP17i=cytochrome P450 17A1 inhibitor. 
 
 
≥30% 8 (73%) 2 (22%) 6 (55%) 
Post-CYP17i 
Number of evaluable patients 15 17 15 
≥90% 0 0 0 
≥50% 0 3 (18%) 1 (7%) 
≥30% 4 (27%) 4 (24%) 1 (7%) 
  
 
We measured baseline and 12-week circulating tumour cell results in 87 of 124 patients. Compared with 
baseline, 41 (82%) patients maintained favourable circulating tumour cell counts (<5 cells per 7·5 mL of 
blood) at week 12. In the patients with unfavourable counts (≥5 cells per 7·5 mL of blood) at baseline, 14 
(38%) converted to favourable counts, and nine (18%) patients converted from favourable to unfavourable. 
No clear differences in responses between dose levels was noted. When analysed by previous treatment, 
conversion from unfavourable to favourable counts was seen in seven (58%) patients who were both 
chemotherapy and CYP17 inhibitor-naive, in seven (58%) of those who had received chemotherapy but not 
a CYP17 inhibitor, and no patients who had been previously treated with a CYP17 inhibitor. However, 16 
(73%) patients who had received a CYP17 inhibitor maintained favourable counts (table 5). 
 
Table 5. 
CTC conversion rate at week 12: expanded dose levels 
 Chemotherapy-naïve/CYP17i-naive 
(n=37
*
) 
Post-chemotherapy/CYP17i-naive 
(n=32
*
) 
Post-CYP17i 
(n=55
†
) 
<5 at baseline 
Number of 
patients 
18 16 25 
<5 at week 12 15 (88%) 10 (91%) 16 (73%) 
≥5 at week 12 2 (12%) 1 (9%) 6 (27%) 
NA at week 12 1 5 3 
≥5 at baseline 
Number of 
patients 
16 13 24 
<5 at week 12 7 (58%) 7 (58%) 0 
≥5 at week 12, 5 (42%) 5 (42%) 13 (100%) 
NA at week 12 4 1 11 
Data are number of patients (%), unless otherwise indicated. CTC=circulating tumour cell. NA=not assessable. CTC count is expressed 
as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. 
*Total number includes three patients with missing baseline. 
†Total number includes six patients with missing baseline. 
 
Using the PCWG2 criteria
19
 of a 25% increase or higher in PSA from nadir, the median time to PSA 
progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for 
patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for 
those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for 
those who had received a CYP17 inhibitor (figure 4). Median time to PSA progression, defined as a 25% 
increase from baseline representing an increase of ≥2 ng/mL, was not reached for any of the subgroups 
(appendix). 
  
 
 
 
Median time to radiological progression was not reached for patients who were naive to both chemotherapy 
and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received 
chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a 
CYP17 inhibitor (figure 5). 
 
 
The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124). Castrate 
concentrations were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111). 
  
 
Discussion 
Findings from this phase 1–2 trial of 134 patients showed that ODM-201 has an encouraging tolerability and 
anticancer profile in men with metastatic castration-resistant prostate cancer. 
ODM-201 was well tolerated up to the highest prespecified daily dose of 1800 mg and a maximum tolerated 
dose was not reached; no dose-limiting toxic effects were noted and dose escalation was discontinued 
because of a plasma concentration plateau of ODM-201. Most adverse events were grade 1–2, and the 
adverse event profile did not differ between dose levels. Many of the noted adverse events (eg, fatigue, 
diarrhoea, decreased appetite, nausea) might also be deemed disease-related and have been consistently 
noted in trials of patients with prostate cancer.6, 8, 21 The overall pattern of tolerability with next-generation AR 
axis inhibitors is a clear advantage for patients with metastatic castration-resistant prostate cancer, 
particularly since elderly patients (aged ≥70 years) have the highest probability of developing prostate 
cancer.22 
No seizures were noted during this trial. This is in contrast to other recently developed AR inhibitors, which 
have shown to penetrate the blood–brain barrier in preclinical pharmacokinetic in vivo models, such as ARN-
50923 and enzalutamide.8,24 In the case of enzalutamide, seizures were reported in three (2%) of 140 patients 
receiving higher doses of drug (360 mg, 480 mg, 600 mg per day) during a phase 1–2 trial, with seizures 
also being reported in seven (1%) of 800 patients in the phase 3 AFFIRM trial,8 which used a lower dose 
(160 mg/day). In the placebo-controlled phase 3 PREVAIL trial two seizures,25 one in each treatment group, 
were reported. Patients with a history or risk of seizure were excluded from these trials, whereas patients 
with medical history of seizures were allowed to enter the present ARADES trial (three patients had history of 
seizures). The hypothesis for risk of seizure associated with enzalutamide and ARN-509 is derived from 
preclinical data showing that both agents bind to and potentially inhibit γ-aminobutyric acid (GABA)-gated 
chloride channels in the brain.23,26 The mechanisms underlying the difference between ODM-201 and ARN-
509 and enzalutamide are not yet understood, but might be related to the unique chemical structure of ODM-
201, which has negligible penetration of the blood–brain barrier in pharmacokinetic studies in mice and in 
quantitative whole-body autoradiography in rats.18,19 This hypothesis needs be confirmed in a large phase 3 
trial. 
Antitumour activity, shown by a reduction of at least 50% in PSA, was noted in all doses and all treatment 
stratification subgroups. The soft tissue and bone lesion data, as well as time to PSA and radiological 
progression, provide supportive evidence for the acivity of ODM-201. Furthermore, more than a third of 
patients converted to favourable circulating tumour cell counts at week 12 and about four-fifths maintained 
favourable circulating tumour cell counts. No obvious dose-related activity benefits were recorded in the 
overall population, but the 1400 mg daily dose produced the greatest PSA response rates in patients who 
had not been previously treated with chemotherapy or CYP17 inhibitors. We noted the highest antitumour 
activity with ODM-201 in the such patients and the lowest in those who had received CYP17 inhibitors, which 
is consistent with other reports correlating activity in this patient population.24, 27 Additionally, the data are 
consistent with reports of cross-resistance with sequential treatment of enzalutamide and CYP17 inhibitors in 
metastatic castration-resistant prostate cancer.28, 29, 30, 31 Because abiraterone and ODM-201 both target the AR 
axis, the mechanism behind the absence of activity with ODM-201 in patients who have received CYP17 
inhibitors might be at the AR level. Patients treated with abiraterone while having progressive disease had 
increased concentrations of PSA, which could be due to AR activation32. On the other hand, AR splice 
variants33 and increased steroidogenesis have also been reported to mediate cross-resistance between 
abiraterone and antiandrogens. 33, 34  
The main limitation of our trial is the open-label, with no control group design, which is typical for phase 1–2 
studies. However, this design was sufficient to provide an initial anticancer activity and safety profile of ODM-
201, and to inform potential future trial development. Another limitation is that although anticancer activity, 
  
 
pharmacokinetics, and tolerability were recorded, the quality-of-life measurements were missing from the 
trial. 
In summary, findings from this phase 1–2 trial show that ODM-201 is well tolerated and exhibits high 
antitumour activity in both chemotherapy-naive patients and chemotherapy-treated patients (panel). 
Additionally, it further confirms that inhibition of the AR pathway is an effective treatment strategy for patients 
with progressive metastatic castration-resistant prostate cancer. A phase 3 randomised trial is planned to 
study ODM-201, at a planned dose of 1200 mg daily, versus placebo in men with non-metastatic castration-
resistant prostate cancer. 
 
Panel 
Research in context 
Systematic review 
We did not do a formal systematic review in the planning of this trial. The design of our study was informed 
by strong evidence that inhibition of androgen receptor (AR) signalling could provide an effective treatment 
strategy for metastatic castration-resistant prostate cancer (March, 2011). At this time, emerging 
evidence
10,16
 suggested AR overexpression played an important role in the development of metastatic 
castration-resistant prostate cancer. Additionally, early phase clinical trial data suggested encouraging 
antitumour activity for initial second-generation AR inhibitors.
24
 Therefore, there was interest in pursuing 
second-generation AR inhibitors as a possible therapeutic strategy in metastatic castration-resistant prostate 
cancer. We did a comprehensive scientific literature search of PubMed when writing our report in January, 
2014, to identify published articles in English with the MeSH terms “Prostatic Neoplasms, Castration-
Resistant”; “Receptors, Androgen”; “Clinical Trial, Phase III”; “abiraterone acetate”; “Provenge”; “MDV3100”; 
“enzalutamide”; “ARN-509”; “cabazitaxel”; “denosumab”; and “radium 223”; we discuss our results in the 
context of these publications and highlight any notable differences. 
Interpretation 
Findings from this phase 1–2 analysis show that ODM-201 has encouraging antitumour activity in both 
chemotherapy-naive patients and chemotherapy-treated men with metastatic castration-resistant prostate 
cancer. ODM-201 had a favourable safety profile and no seizures were noted. These results support further 
investigation of ODM-201 in a larger phase 3 trial in men with castration-resistant prostate cancer. 
Contributions 
KF, CM, AV, LM, PL, JA, and MM contributed to the study concept and design. KF, CM, PB, RJ, VK, NJ, JG, 
AP, TT, and TE recruited patients to the trial. JA was responsible for statistical analysis. KF, PB, TT, AV, LM, 
JA, PL, and MM participated in assessment and interpretation of the data. All authors have reviewed and 
contributed to the final version of this report. The authors take full responsibility for the scope, direction, and 
content of the report. 
Declaration of interests 
KF and CM have received consultancy fees from Orion Pharma. PB has received honoria for participation in 
advisory board meetings of Orion Pharma, GlaxoSmithKline, Pfizer, and Novartis. VK has received payment 
for speaker bureau from Astellas, Bayer, Roche Finland, Pfizer, MSD, Merck, and Sanofi-Aventis. JG has 
received consultacy fees from Astellas, Sanofi and Bayer, payment for speaker bureau from Bayer, and 
reseach grant support paid to his institution from Johnson & Johnson. AP has received honoraria for 
participation in advisory board meetings of Astellas and Pfizer. TT has received consultancy fees from Orion 
Pharma, Astellas, Amgen, Sanofi, and Janssen. TE has received consultacy fees and travel support from 
  
 
Astellas and Janssen. PL was employee of Endo Pharmaceuticals during the conduct of the trial. JA and AV 
are employees of Orion Corporation Orion Pharma. LM and MM are employees of Orion Corporation Orion 
Pharma and own stock in Orion Corporation. All other authors declare no competing interests. 
Acknowledgments 
The authors thank all patients and their families for participating in this trial and all study investigators and 
site staff, and data and safety monitoring committee for the trial. The trial was supported by Orion 
Corporation Orion Pharma in collaboration with Endo Pharmaceuticals. Medical writing assistance was 
provided by Tyrone Daniel of Bioscript Medical Ltd; this was funded by Orion Corporation. We thank Andrew 
Wighton, Orion Corporation Orion Pharma, for reviewing the language. 
 
Supplementary appendix.  
 
 
 
 
